ResearchPA-400 Real-World Outcomes and Predictors of Bispecific Antibody Therapy Response in a Racially Diverse Multiple Myeloma Cohort
ResearchPA-351 Phase II Study of Daratumumab, Clarithromycin, Pomalidomide, and Dexamethasone (D-ClaPd) in Multiple Myeloma Patients Previously Exposed to Daratumumab
ResearchOA-02 A CD4 Dominant, T-Helper-Skewed T Cell State Underlies Movement and Neurocognitive Toxicity After BCMA-Directed CAR-T Therapy in Multiple Myeloma
ResearchAnakinra Prophylaxis during BCMA-Directed CAR-T Therapy: A Two-Center Analysis of Toxicity and Outcomes
ResearchResponse and outcomes of patients with IDH1/2- mutated accelerated/blast-phase myeloproliferative neoplasms
ResearchAssessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy
ResearchOutcomes of Patients with Accelerated/Blast-Phase MPNs That Received Allogeneic Stem-Cell Transplant in the Current Era of Myeloid Therapies